<?xml version='1.0' encoding='utf-8'?>
<document id="8039111"><sentence text="The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer."><entity charOffset="15-27" id="DDI-PubMed.8039111.s1.e0" text="cyclosporine" /><entity charOffset="55-66" id="DDI-PubMed.8039111.s1.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.8039111.s1.e0" e2="DDI-PubMed.8039111.s1.e0" /><pair ddi="false" e1="DDI-PubMed.8039111.s1.e0" e2="DDI-PubMed.8039111.s1.e1" /></sentence><sentence text="The authors compared the pharmacokinetics of doxorubicin when administered with and without concomitant high dose cyclosporine for multidrug resistant (MDR) tumor modulation in small cell lung cancer"><entity charOffset="45-56" id="DDI-PubMed.8039111.s2.e0" text="doxorubicin" /><entity charOffset="114-126" id="DDI-PubMed.8039111.s2.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.8039111.s2.e0" e2="DDI-PubMed.8039111.s2.e0" /><pair ddi="false" e1="DDI-PubMed.8039111.s2.e0" e2="DDI-PubMed.8039111.s2.e1" /></sentence><sentence text="" /><sentence text="Eight patients with small cell lung cancer served as their own controls and were studied first during an initial course of doxorubicin without cyclosporine, and then subsequently during a cyclosporine-modulated doxorubicin course"><entity charOffset="123-134" id="DDI-PubMed.8039111.s4.e0" text="doxorubicin" /><entity charOffset="143-155" id="DDI-PubMed.8039111.s4.e1" text="cyclosporine" /><entity charOffset="188-200" id="DDI-PubMed.8039111.s4.e2" text="cyclosporine" /><entity charOffset="211-222" id="DDI-PubMed.8039111.s4.e3" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.8039111.s4.e0" e2="DDI-PubMed.8039111.s4.e0" /><pair ddi="false" e1="DDI-PubMed.8039111.s4.e0" e2="DDI-PubMed.8039111.s4.e1" /><pair ddi="false" e1="DDI-PubMed.8039111.s4.e0" e2="DDI-PubMed.8039111.s4.e2" /><pair ddi="false" e1="DDI-PubMed.8039111.s4.e0" e2="DDI-PubMed.8039111.s4.e3" /><pair ddi="false" e1="DDI-PubMed.8039111.s4.e1" e2="DDI-PubMed.8039111.s4.e1" /><pair ddi="false" e1="DDI-PubMed.8039111.s4.e1" e2="DDI-PubMed.8039111.s4.e2" /><pair ddi="false" e1="DDI-PubMed.8039111.s4.e1" e2="DDI-PubMed.8039111.s4.e3" /><pair ddi="false" e1="DDI-PubMed.8039111.s4.e2" e2="DDI-PubMed.8039111.s4.e2" /><pair ddi="false" e1="DDI-PubMed.8039111.s4.e2" e2="DDI-PubMed.8039111.s4.e3" /></sentence><sentence text=" All patients received cyclophosphamide and vincristine in each course"><entity charOffset="23-39" id="DDI-PubMed.8039111.s5.e0" text="cyclophosphamide" /><entity charOffset="44-55" id="DDI-PubMed.8039111.s5.e1" text="vincristine" /><pair ddi="false" e1="DDI-PubMed.8039111.s5.e0" e2="DDI-PubMed.8039111.s5.e0" /><pair ddi="false" e1="DDI-PubMed.8039111.s5.e0" e2="DDI-PubMed.8039111.s5.e1" /></sentence><sentence text=" Doxorubicin was administered as a 1-hour infusion after a 2-hour cyclosporine loading infusion, and cyclosporine was infused continuously for the next 48 hours"><entity charOffset="1-12" id="DDI-PubMed.8039111.s6.e0" text="Doxorubicin" /><entity charOffset="101-113" id="DDI-PubMed.8039111.s6.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.8039111.s6.e0" e2="DDI-PubMed.8039111.s6.e0" /><pair ddi="false" e1="DDI-PubMed.8039111.s6.e0" e2="DDI-PubMed.8039111.s6.e1" /></sentence><sentence text=" Serum concentrations of doxorubicin, doxorubicinol, and cyclosporine all were assayed by high-pressure liquid chromatography"><entity charOffset="25-36" id="DDI-PubMed.8039111.s7.e0" text="doxorubicin" /><entity charOffset="38-51" id="DDI-PubMed.8039111.s7.e1" text="doxorubicinol" /><entity charOffset="57-69" id="DDI-PubMed.8039111.s7.e2" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.8039111.s7.e0" e2="DDI-PubMed.8039111.s7.e0" /><pair ddi="false" e1="DDI-PubMed.8039111.s7.e0" e2="DDI-PubMed.8039111.s7.e1" /><pair ddi="false" e1="DDI-PubMed.8039111.s7.e0" e2="DDI-PubMed.8039111.s7.e2" /><pair ddi="false" e1="DDI-PubMed.8039111.s7.e1" e2="DDI-PubMed.8039111.s7.e1" /><pair ddi="false" e1="DDI-PubMed.8039111.s7.e1" e2="DDI-PubMed.8039111.s7.e2" /></sentence><sentence text=" Pharmacokinetic analysis of doxorubicin included area under the curve (AUC), clearance, apparent volume of distribution at steady state (Vss), and elimination half-life (T1/2)"><entity charOffset="29-40" id="DDI-PubMed.8039111.s8.e0" text="doxorubicin" /></sentence><sentence text=" The percent of change and surviving fraction of leukocyte count and platelets were determined as pharmacodynamic indices" /><sentence text="" /><sentence text="Cyclosporine modulation increased the AUC0-36 of doxorubicin by 48% (P = 0"><entity charOffset="0-12" id="DDI-PubMed.8039111.s11.e0" text="Cyclosporine" /><entity charOffset="49-60" id="DDI-PubMed.8039111.s11.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.8039111.s11.e0" e2="DDI-PubMed.8039111.s11.e0" /><pair ddi="false" e1="DDI-PubMed.8039111.s11.e0" e2="DDI-PubMed.8039111.s11.e1" /></sentence><sentence text="042) and the AUC0-36 of doxorubicinol by 443% (P = 0"><entity charOffset="24-37" id="DDI-PubMed.8039111.s12.e0" text="doxorubicinol" /></sentence><sentence text="0001), whereas the doxorubicin clearance declined by 37% (P = 0"><entity charOffset="19-30" id="DDI-PubMed.8039111.s13.e0" text="doxorubicin" /></sentence><sentence text="0495)" /><sentence text=" No difference was found in the Vss or T1/2 for doxorubicin when cyclosporine was added to the regimen"><entity charOffset="48-59" id="DDI-PubMed.8039111.s15.e0" text="doxorubicin" /><entity charOffset="65-77" id="DDI-PubMed.8039111.s15.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.8039111.s15.e0" e2="DDI-PubMed.8039111.s15.e0" /><pair ddi="false" e1="DDI-PubMed.8039111.s15.e0" e2="DDI-PubMed.8039111.s15.e1" /></sentence><sentence text=" The ratio of the doxorubicinol AUC0-36 to the doxorubicin AUC0-36 increased significantly with cyclosporine modulation (8"><entity charOffset="47-58" id="DDI-PubMed.8039111.s16.e0" text="doxorubicin" /><entity charOffset="96-108" id="DDI-PubMed.8039111.s16.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.8039111.s16.e0" e2="DDI-PubMed.8039111.s16.e0" /><pair ddi="false" e1="DDI-PubMed.8039111.s16.e0" e2="DDI-PubMed.8039111.s16.e1" /></sentence><sentence text="88 vs" /><sentence text=" 2" /><sentence text="19; P = 0" /><sentence text="001)" /><sentence text=" Drug-related toxicity was also greater with the cyclosporine-modulated course of doxorubicin"><entity charOffset="49-61" id="DDI-PubMed.8039111.s21.e0" text="cyclosporine" /><entity charOffset="82-93" id="DDI-PubMed.8039111.s21.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.8039111.s21.e0" e2="DDI-PubMed.8039111.s21.e0" /><pair ddi="false" e1="DDI-PubMed.8039111.s21.e0" e2="DDI-PubMed.8039111.s21.e1" /></sentence><sentence text=" A 91% reduction in the leukocyte count followed the modified course, compared with an 84% reduction following the initial course (P = 0" /><sentence text="0074)" /><sentence text=" A more prolonged and greater degree of myelosuppression was observed and a significant relationship was found between the systemic exposure to doxorubicin (defined by AUC) and the surviving fraction of the leukocyte count (r = -0"><entity charOffset="144-155" id="DDI-PubMed.8039111.s24.e0" text="doxorubicin" /></sentence><sentence text="69; P = 0" /><sentence text="006)" /><sentence text=" Similarly, the reduction in the platelet count was significantly greater after the cyclosporine-modulated course (72"><entity charOffset="84-96" id="DDI-PubMed.8039111.s27.e0" text="cyclosporine" /></sentence><sentence text="8%) than after the initial course (36" /><sentence text="4%) (P = 0" /><sentence text="0016)" /><sentence text=" A significant correlation was found between the AUC of doxorubicinol and the surviving fraction of platelets (r = -0"><entity charOffset="56-69" id="DDI-PubMed.8039111.s31.e0" text="doxorubicinol" /></sentence><sentence text="71; P = 0" /><sentence text="004)" /><sentence text=" In addition, patients showed decreased performance status associated with significant weight loss and severe myalgias" /><sentence text="" /><sentence text="The addition of high dose cyclosporine for MDR modulation resulted in the significant alteration of doxorubicin disposition and remarkable toxicity in all patients"><entity charOffset="26-38" id="DDI-PubMed.8039111.s36.e0" text="cyclosporine" /><entity charOffset="100-111" id="DDI-PubMed.8039111.s36.e1" text="doxorubicin" /><pair ddi="false" e1="DDI-PubMed.8039111.s36.e0" e2="DDI-PubMed.8039111.s36.e0" /><pair ddi="false" e1="DDI-PubMed.8039111.s36.e0" e2="DDI-PubMed.8039111.s36.e1" /></sentence><sentence text=" The mechanisms responsible for the decreased doxorubicin clearance may include cyclosporine's ability both to interfere with P-glycoprotein in normal tissues and to selectively inhibit the cytochrome P-450 enzyme system"><entity charOffset="46-57" id="DDI-PubMed.8039111.s37.e0" text="doxorubicin" /></sentence><sentence text=" Further study of this potentially significant drug-drug interaction is warranted" /><sentence text="" /></document>